Zwitterionic Polymer–Factor VIII Conjugates for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A, such as frequent dosing of Factor VIII, are undesirable due to patient compliance issues and the development of antibodies, necessitating a need for improved bioavailability and pharmacokinetic properties to extend the in vivo half-life of Factor VIII while maintaining biological activity.
Innovation Solution
Development of a recombinant Factor VIII (rFVIII) conjugate with a zwitterionic polymer, specifically synthesized with phosphorylcholine monomers, covalently bonded through cysteine residues in the B-domain, forming a branched polymer structure with a molecular weight of 300,000 to 1,750,000 daltons, enhancing bioavailability and half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Factor VIII is administered frequently to maintain therapeutic levels, then bleeding control is improved, but patient compliance deteriorates due to frequent clinic visits and injections
Solution Approach 1:
The patent changes the pharmacokinetic parameters of Factor VIII by conjugating it with zwitterionic polymers, specifically extending the half-life from approximately 11 hours to at least 20 hours. This parameter change allows less frequent dosing (once weekly or less) while maintaining therapeutic efficacy, thereby improving patient compliance without sacrificing bleeding control reliability
2Duration of action of stationary object
If PEGylation is used to extend half-life, then solubility and stability are improved, but immunogenicity increases
Solution Approach 1:
The patent employs zwitterionic polymers containing both positively charged (e.g., trimethylammonium) and negatively charged (e.g., phosphorylcholine) groups in a composite structure. This composite material design provides extended half-life through increased solubility and stability while the zwitterionic balance reduces immunogenicity compared to PEGylation, as the net neutral charge minimizes immune system recognition
Solution Approach 2:
The patent changes the chemical composition parameters by replacing PEG with zwitterionic polymer chains that have different physicochemical properties. The zwitterionic structure with balanced positive and negative charges alters the interaction with the immune system, reducing antibody formation while maintaining the pharmacokinetic benefits of extended circulation half-life
3Reliability
If full length recombinant FVIII is administered, then therapeutic efficacy is maintained, but half-life remains short requiring frequent dosing
Solution Approach 1:
The patent introduces zwitterionic polymers as intermediary molecules that conjugate to Factor VIII through cysteine residues in the B-domain. This intermediary polymer layer extends the half-life of Factor VIII by reducing renal clearance and protecting from degradation, while the conjugation strategy is designed to preserve the biological activity and therapeutic efficacy of the full-length FVIII
Data Source
Figure 1
Figure 2
AI summary
The present invention provides multi-armed high MW polymers containing hydrophilic groups.